{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:52:03Z","timestamp":1790275923076,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clml.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:36:37Z","timestamp":1749209797000},"page":"763-774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | Elderly Acute Lymphoblastic Leukemia: Low-Dose Chemotherapy and Immunotherapy Combinations"],"prefix":"10.1016","volume":"25","author":[{"given":"Perrine","family":"Moyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude-Marie","family":"Fourmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Freiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2025.06.001_bib0001","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.001_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.06.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2025.06.001_bib0004","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.06.001_bib0005","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O\u2019Brien","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0006","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII \/ECOG 2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2015.230","article-title":"Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival","volume":"30","author":"Dinmohamed","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.06.001_bib0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2015.11.012","article-title":"Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group","volume":"41","author":"Ribera","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2025.06.001_bib0009","doi-asserted-by":"crossref","unstructured":"Kozlowski P., Lennmyr E., Ahlberg L., et al. Age but not Philadelphia positivity impairs outcome in older\/elderly patients with acute lymphoblastic leukemia in Sweden. Eur J Haematol. doi:10.1111\/ejh.12896.","DOI":"10.1111\/ejh.12896"},{"issue":"11","key":"10.1016\/j.clml.2025.06.001_bib0010","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2012.080432","article-title":"Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts","volume":"98","author":"Chiaretti","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2025.06.001_bib0011","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","article-title":"A population-based cytogenetic study of adults with acute lymphoblastic leukemia","volume":"115","author":"Moorman","year":"2010","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.clml.2025.06.001_bib0012","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.24.00500","article-title":"Impact of age on pharmacogenomics and treatment outcomes of B-cell acute lymphoblastic leukemia","volume":"42","author":"Yoshimura","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0013","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-99-111954","article-title":"Comorbidities are frequent in older patients with De novo acute lymphoblastic leukemia (ALL) and correlate with induction mortality: analysis of more than 1200 patients from GMALL data bases","volume":"132","author":"Wermann","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0014","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2022-158934","article-title":"Outcome of 841 older patients (>55 yrs) with newly diagnosed ph\/BCR-ABL negative ALL prospectively treated according to pediatric-based, age-adapted GMALL protocols","volume":"140","author":"Goekbuget","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2025.06.001_bib0015","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2025.06.001_bib0016","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.06.001_bib0017","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1080\/10428194.2018.1538505","article-title":"Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL","volume":"60","author":"Kim","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.clml.2025.06.001_bib0018","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood.V120.21.1493.1493","volume":"120","author":"Goekbuget","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.06.001_bib0019","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clml.2023.10.011","article-title":"SOHO State of the art updates and next questions | approach to older adults with phildadelphia-chromosome negative acute lymphoblastic leukemia","volume":"24","author":"Shimony","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2025.06.001_bib0020","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2352-3026(23)00064-9","article-title":"Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past","volume":"10","author":"Short","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0021","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2025.06.001_bib0022","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.001_bib0023","unstructured":"Food and Drug Administration. FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell. Accessed June 14, 2024."},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0024","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0026","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0027","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy","year":"2022","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.clml.2025.06.001_bib0028","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II trial of Blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.001_bib0029","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-024-01597-8","article-title":"Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial","volume":"17","author":"Lu","year":"2024","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.001_bib0030","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ajh.27576","article-title":"Hyper- CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0031","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2023-180472","article-title":"Dose reduced chemotherapy in sequence with Blinatumomab for newly diagnosed older patients with ph\/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial","volume":"142","author":"Goekbuget","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0032","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/blood-2022-156080","volume":"140","author":"Jabbour","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027500","article-title":"Up-front Blinatumomab improves MRD clearance and outcome in adult ph\u2212 B-lineage ALL: the GIMEMA LAL2317 Phase 2 study","author":"Bassan","year":"2025","journal-title":"Blood J."},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0034","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2022-159397","article-title":"Blinatumomab during consolidation in high-risk Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) adult patients: a two-cohort comparison within the Graall-2014\/B study","volume":"140","author":"Boissel","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0035","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.26634","article-title":"Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10\u22124 and higher","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2025.06.001_bib0036","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.06.001_bib0037","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/01.HS9.0000844352.62588.a4","article-title":"P366: blinatumomab added to prephase and consolidation therapy in newly diagnosed precursor B-all in adults. A phase ii hovon trial","volume":"6","author":"Rijneveld","year":"2022","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0038","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.34666","article-title":"Lower leukemia burden maximizes the impact of blinatumomab therapy","volume":"129","author":"Logan","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0039","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0040","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2024-193681","article-title":"Evaluation of AZD0486, a novel CD19xCD3 T-cell engager, in relapsed\/refractory diffuse large B-cell lymphoma in an ongoing first-in-Human phase 1 study: high complete responses seen in CAR-T-naive and CAR-T-exposed patients","volume":"144","author":"Gaballa","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.06.001_bib0041","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.06.001_bib0042","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molimm.2014.09.014","article-title":"Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies","volume":"67","author":"Shor","year":"2015","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.001_bib0043","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus standard care for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2025.06.001_bib0044","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2025.06.001_bib0045","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/cncr.31249","article-title":"Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2025.06.001_bib0046","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0047","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3324\/haematol.2021.280433","article-title":"Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin","volume":"107","author":"Kayser","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2025.06.001_bib0048","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-020-00345-8","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden","volume":"10","author":"DeAngelo","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.06.001_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2024.12.016","article-title":"Inotuzumab Ozogamicin as first-line therapy in acute lymphoblastic leukemia","author":"Jabbour","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2025.06.001_bib0050","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.001_bib0051","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab Ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome\u2013Negative B-precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.clml.2025.06.001_bib0052","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab Ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome\u2013Negative B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.06.001_bib0053","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.06.001_bib0054","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.06.001_bib0055","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk factors for development of and progression of hepatic Veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0056","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0057","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2022-170730","article-title":"Adct-602, a CD22 targeting antibody drug conjugate bound to PBD toxin in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: a phase 1 trial","volume":"140","author":"Jain","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.06.001_bib0058","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0059","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.06.001_bib0060","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 Inhibitor sensitivity and bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.clml.2025.06.001_bib0061","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41419-019-1801-0","article-title":"Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling","volume":"10","author":"Seyfried","year":"2019","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.clml.2025.06.001_bib0062","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0063","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","article-title":"Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia","volume":"79","author":"Diaz-Flores","year":"2019","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0064","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","article-title":"A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"Short","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.06.001_bib0065","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","article-title":"Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia","volume":"9","author":"Luskin","year":"2025","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0066","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1182\/blood-2023-174269","article-title":"Mini-hyper-CVD plus venetoclax for treatment of older adults with newly diagnosed ph-negative B-ALL or T-ALL","volume":"142","author":"Luskin","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.06.001_bib0067","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"10299","key":"10.1016\/j.clml.2025.06.001_bib0068","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"The Lancet"},{"issue":"23","key":"10.1016\/j.clml.2025.06.001_bib0069","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.06.001_bib0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0071","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood-2024-201784","article-title":"CD19-CAR T cells As definitive consolidation for older adults with B-cell acute lymphoblastic leukemia in first complete remission: a pilot study","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.06.001_bib0072","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2020003482","article-title":"Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia","volume":"6","author":"Grover","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0073","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1182\/blood-2024-210124","article-title":"Sequential CD19 and CD22 CAR-T therapy in relapsed\/refractory acute lymphoblastic leukemia","volume":"144","author":"Yang","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.06.001_bib0074","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clml.2025.06.001_bib0075","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/blood-2008-04-149286","article-title":"Patients\u2019 age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group","volume":"112","author":"Burmeister","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.06.001_bib0076","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0077","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","article-title":"Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study","volume":"20","author":"Delannoy","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.06.001_bib0078","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome\u2013positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0079","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2018-99-114552","article-title":"Nilotinib (Tasigna\u00ae) and low intensity chemotherapy for first-line treatment of elderly patients with BCR-ABL1-positive acute lymphoblastic leukemia: final results of a prospective multicenter trial (EWALL-PH02)","volume":"132","author":"Ottmann","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.06.001_bib0080","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs Imatinib in frontline Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0081","first-page":"413","article-title":"Should ponatinib be the standard-of-care tyrosine kinase inhibitor in Ph+ ALL?","volume":"22","author":"Jabbour","year":"2024","journal-title":"Clin Adv Hematol Oncol HO"},{"issue":"9","key":"10.1016\/j.clml.2025.06.001_bib0082","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.06.001_bib0083","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","article-title":"INCB84344-201: ponatinib and steroids in frontline therapy for unfit patients with ph+ acute lymphoblastic leukemia","volume":"6","author":"Martinelli","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.clml.2025.06.001_bib0084","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013Blinatumomab for ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.06.001_bib0085","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the Dasatinib-Blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.06.001_bib0086","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.06.001_bib0087","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"36","key":"10.1016\/j.clml.2025.06.001_bib0088","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of Ponatinib and Blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.001_bib0089","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/ajh.27463","article-title":"A phase 2 trial of mini-hyper- CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia","volume":"99","author":"Jen","year":"2024","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.001_bib0090","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood-2024-207892","article-title":"Efficacy and toxicity of frontline Ponatinib plus Blinatumomab for adult ph+ ALL patients of all ages. Intermediate analysis of the Gimema ALL2820","volume":"144","author":"Chiaretti","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0091","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000492941","article-title":"Long-term molecular remission achieved by antibody anti-CD22 and Ponatinib in a patient affected by ph\u2019+ acute lymphoblastic leukemia relapsed after second allogeneic hematopoietic stem cell transplantation: a case report","volume":"63","author":"Pirosa","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clml.2025.06.001_bib0092","first-page":"1","article-title":"Efficacy of Inotuzumab Ozogamicin plus Ponatinib followed by allogeneic stem cell transplantation in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Piccaluga PP, ed","volume":"2021","author":"Micheva","year":"2021","journal-title":"Case Rep Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.001_bib0093","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2360843","article-title":"Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib","volume":"29","author":"Tachibana","year":"2024","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.clml.2025.06.001_bib0094","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.001_bib0095","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cncr.33321","article-title":"Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome\u2013positive relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Stock","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.06.001_bib0096","article-title":"Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"17","author":"Ueda","year":"2022","journal-title":"Leuk Res Rep"},{"issue":"13","key":"10.1016\/j.clml.2025.06.001_bib0097","first-page":"4674","article-title":"Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate","volume":"9","author":"Pfeifer","year":"2003","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"10.1016\/j.clml.2025.06.001_bib0098","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1182\/blood.2024024838","article-title":"Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia","volume":"144","author":"Walczak","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0099","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome\u2013positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0100","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/hon.3136","article-title":"A five-gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia","volume":"41","author":"Sapienza","year":"2023","journal-title":"Hematol Oncol"},{"issue":"29","key":"10.1016\/j.clml.2025.06.001_bib0101","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038985","article-title":"Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report","volume":"103","author":"Liu","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.clml.2025.06.001_bib0102","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.2024025800","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome\u2013positive acute leukemia","volume":"145","author":"Luskin","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.06.001_bib0103","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/asheducation-2016.1.573","article-title":"Treatment of older patients with acute lymphoblastic leukemia","volume":"2016","author":"G\u00f6kbuget","year":"2016","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.clml.2025.06.001_bib0104","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","article-title":"Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.06.001_bib0105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3324\/haematol.2023.283814","article-title":"Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia","volume":"109","author":"Koslowski","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0106","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2021.279851","article-title":"Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study","volume":"107","author":"Cerrano","year":"2022","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.clml.2025.06.001_bib0107","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2024024493","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study","volume":"144","author":"Bhatla","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.06.001_bib0108","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/cam4.4478","article-title":"Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: phase 2 study","volume":"11","author":"Boissel","year":"2022","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.clml.2025.06.001_bib0109","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7 -targeted chimeric antigen receptor-T cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.001_bib0110","article-title":"mRNA-engineered CD5-CAR-\u03b3\u03b4tCD5- cells for the immunotherapy of T-cell acute lymphoblastic leukemia","author":"Zhu","year":"2024","journal-title":"Adv Sci"},{"issue":"1","key":"10.1016\/j.clml.2025.06.001_bib0111","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","volume":"31","author":"Pan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.06.001_bib0112","article-title":"Anti-CD7 allogeneic WU-CART-007 in patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma: a phase 1\/2 trial","author":"Ghobadi","year":"2024","journal-title":"Res Sq"},{"issue":"12","key":"10.1016\/j.clml.2025.06.001_bib0113","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.clml.2025.06.001_bib0114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00127","article-title":"First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia","author":"Numan","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.001_bib0115","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.06.001_bib0116","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022017948","article-title":"IL7-receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK-inhibition","author":"Courtois","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.06.001_bib0117","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jha2.143","article-title":"Ruxolitinib is effective in the treatment of a patient with refractory T-ALL","volume":"2","author":"Jaramillo","year":"2021","journal-title":"eJHaem"},{"issue":"5","key":"10.1016\/j.clml.2025.06.001_bib0118","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1\u20132a trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.001_bib0119","doi-asserted-by":"crossref","first-page":"96","DOI":"10.37349\/etat.2024.00207","article-title":"CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia","volume":"5","author":"Kotemul","year":"2024","journal-title":"Explor Target Anti-Tumor Ther"},{"key":"10.1016\/j.clml.2025.06.001_bib0120","article-title":"Venetoclax and bortezomib in relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia","volume":"3","author":"La Starza","year":"2019","journal-title":"JCO Precis Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:37:21Z","timestamp":1776397041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":120,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2152265025002010"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Elderly Acute Lymphoblastic Leukemia: Low-Dose Chemotherapy and Immunotherapy Combinations","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}